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Abstract
Background Endoscopic ultrasound-guided ﬁne-needle
aspiration (EUS-FNA) of mediastinal lymphadenopathy
has been shown to be a valuable diagnostic tool in high-
volume EUS centers (C50 mediastinal EUS-FNA/endos-
copist/year). Our goal was to assess the diagnostic accuracy
of EUS-FNA and its impact on clinical management and
costs in low-volume EUS centers (\50 mediastinal EUS-
FNA/endoscopist/year).
Methods Consecutive patients referred to two Dutch
endoscopy centers in the period 2002–2008 for EUS-FNA
of mediastinal lymphadenopathy were reviewed. The gold
standard for a cytological diagnosis was histological con-
ﬁrmation or clinical follow-up of more than 6 months with
repeat imaging. The impact of EUS-FNA on clinical
management was subdivided into a positive impact by
providing (1) adequate cytology that inﬂuenced the deci-
sion to perform surgery or (2) a diagnosis of a benign
inﬂammatory disorder, and a negative impact which was
subdivided into (1) false-negative or inconclusive cytology
or (2) an adequate cytological diagnosis that did not
inﬂuence patient management. Costs of an alternative
diagnostic work-up without EUS-FNA, as established
by an expert panel, were compared to costs of the actual
work-up.
Results In total, 213 patients (71% male, median
age = 61 years, range = 23–88 years) underwent EUS-
FNA. Sensitivity, speciﬁcity, and negative and positive
predictive values were 89%, 100%, 80%, and 100%,
respectively. EUS-FNA had a positive impact on clinical
management in 84% of cases by either inﬂuencing the
decision to perform surgery (49%) or excluding malignant
lymphadenopathy (35%), and a negative impact in 7% of
cases because of inadequate (3%) or false-negative (4%)
cytology. In 9% of cases, EUS-FNA was performed with-
out an established indication. Two nonfatal perforations
occurred (0.9%). Total cost reduction was €100,593, with a
mean cost reduction of €472 (SD = €607) per patient.
Conclusions Mediastinal EUS-FNA can be performed in
low-volume EUS centers without compromising diagnostic
accuracy. Moreover, EUS-FNA plays an important role in
the management of patients with mediastinal lymphade-
nopathy and reduces total diagnostic costs.
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Mediastinal lymphadenopathy
Mediastinal lymphadenopathy may be secondary to
malignancy or inﬂammation. Mediastinoscopy and com-
puted tomography (CT)-guided biopsy can be used for
obtaining tissue, although both techniques have several
limitations and may cause morbidity [1].
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(EUS-FNA) has been proven to be an accurate diagnostic
tool for determining the nature of mediastinal lesions [2–
4]. Its impact on patient management has been studied
mostly in clinical trials with highly deﬁned groups, i.e.,
in patients with lymphadenopathy of unknown origin [5–
7], non-small-cell lung cancer (NSCLC) [8–16], and
esophageal cancer [17]. The majority of these studies
were performed in high-volume centers with experienced
endoscopists performing EUS-FNA [2, 3, 8, 10–12, 14,
16, 17].
It is known that there is a learning curve for EUS(-FNA)
in staging malignancies [18–21]. Moreover, it has been
shown that high-volume EUS centers (C50 EUS/endosco-
pist/year) perform better in staging esophageal cancer than
low-volume centers (\50 EUS/endoscopist/year) [22].
However, whether this issue also applies to EUS-FNA
of mediastinal lymphadenopathy is unknown. Another
important yet underreported topic is the potential of EUS-
FNA to reduce costs by establishing a diagnosis. Only a
few studies have looked into this subject, including only
patients with mediastinal nodes in NSCLC and esophageal
cancer [16, 23–25].
The aim of this study was to assess the diagnostic per-
formance of EUS-FNA in mediastinal lymphadenopathy in
low-volume EUS centers and its impact on clinical man-
agement and costs.
Materials and methods
All consecutive patients who underwent EUS-FNA of
enlarged mediastinal lymph nodes, detected on CT, posi-
tron emission tomography (PET) scan, or previous EUS, in
the period 2002–2008 at the University Medical Center
Utrecht (a tertiary referral center) and the Meander Medical
Center, Amersfoort (a teaching hospital), were reviewed.
Patients were subdivided into two categories according to
the use of EUS-FNA: for staging a malignancy (n = 86) or
diagnosis (n = 145). In the latter, patients presented with
mediastinal nodes of unknown origin or with disseminated
disease for which other staging procedures had already
been performed but cytological conﬁrmation of malig-
nancy was required. In the staging group, patients already
had conﬁrmed malignant disease or were strongly sus-
pected of having a malignancy.
Procedure
EUS-FNA was performed by four endoscopists (MS, FV,
MB, and BO). Each had performed more than 25 EUS-
FNA procedures before the beginning of the study.
Administration of anticoagulants was discontinued 3 days
before the procedure. Patients were placed in the left lateral
decubitus position. Pulse rate and oxygen saturation were
monitored. Patients received conscious sedation with
intravenous midazolam and pethidine.
EUS was performed with linear array echoendoscopes
(GF-UC140P or GF-UCT140, Olympus, Hamburg, Ger-
many). The endoscopist selected the largest and/or the most
malignant-appearing node for FNA. In some cases more
than one enlarged lymph node was aspirated. FNA was
performed with a 22-gauge needle (Echotip Endoscopic
Ultrasound needle, Cook, Limerick, Ireland). The aspirated
material was smeared directly on glass slides, air-dried, and
stained with Diff-Quick stain. Slides were immediately
reviewed by a pathology resident or cytotechnician for
adequacy of the specimen. The procedure was repeated
until adequacy was conﬁrmed.
Accuracy
The gold standard for ﬁnal diagnosis included histology or
a clinical follow-up of at least 6 months, with repeat
imaging to assess disease progression [2–4]. A positive
cytological result was considered true positive if it was
highly suggestive of malignancy in patients with com-
patible clinical progress of the disorder or a response to
chemotherapy or radiation. In patients with a high prob-
ability of an inﬂammatory disorder such as sarcoidosis,
detection of noncaseating granulomas was considered true
positive for sarcoidosis, but in patients suspected for dis-
seminated malignancy, detection of granulomas was con-
sidered true negative for malignancy. Inconclusive or
benign cytology was considered false negative if further
diagnostic workup or clinical follow-up showed signs
positive for malignancy or a benign inﬂammatory disor-
der. Negative cytology was considered to be true negative
when histology did not show any abnormality or when
imaging studies during follow-up showed spontaneous
resolution or lack of progression of mediastinal lymph
nodes. Patients in whom no ﬁnal diagnosis could be made
were excluded from analysis.
Impact on clinical management
A prepuncture diagnosis (diagnosis most likely before
performing EUS-FNA) was obtained from clinical data,
including radiology reports and endoscopy reports, and
compared to the ﬁnal cytodiagnosis. The impact of EUS-
FNA on clinical management was divided into two cate-
gories based on a classiﬁcation by Chen et al. [26]: The
impact was considered to be positive if it provided an
adequate cytological result that (1) inﬂuenced the decision
to perform surgery or start chemotherapy or radiotherapy
or (2) diagnosed a benign inﬂammatory disorder or a
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123reactive lymph node. The impact was considered to be
negative if the cytology (1) provided a false-negative or
inconclusive result and therefore no indication for further
diagnostic investigation or (2) did not inﬂuence patient
management despite adequate cytology.
The impact of the cytological result on patient man-
agement was independently determined for each patient
by a panel that included a gastroenterologist (KT), a
pulmonologist (NS), and a researcher (MH), all of whom
were not involved in the EUS-FNA procedures. In
inconclusive cases, consensus was achieved by a panel
discussion in which a second gastroenterologist (FV) was
involved.
Cost reduction analysis
To assess potential cost reduction by performing EUS-FNA
in the diagnostic evaluation of mediastinal lymphadenop-
athy, the above-mentioned panel determined for each
individual patient which diagnostic tool would have been
used if EUS-FNA had not been available (theoretical
diagnostic work-up). Costs of EUS-FNA, alternative
investigations, hospital stay, anesthesia, and pathology
processing and interpretation were obtained from a stan-
dard price list. The prices were calculated by averaging the
prices of these procedures in ten Dutch medical centers. If
the actual work-up required further diagnostic investiga-
tions, these extra costs were added. Total cost of a com-
plication in the actual work-up comprised the costs of
prolonged hospital admission (€239.15 per day) and addi-
tional investigations and therapy, if necessary. As it is not
possible to predict the course and thereby the costs of a
theoretical complication; we assumed that both actual and
theoretical complications had a similar course and equal
costs [16, 23]. The number of theoretical complications
was calculated from published complication rates (2% for
mediastinoscopy) [1]. The total cost of the actual diag-
nostic work-up, including complications and additional
investigations, was compared with the total cost of the
alternative diagnostic work-up, including theoretical com-
plications. Cost of therapy was not included since both
diagnostic strategies were assumed to have equivalent
outcomes.
Statistical analysis
The cytodiagnosis was compared with the gold standards
for assessment of accuracy. SPSS v15.0 (SPSS Inc., Chi-
cago, IL, USA) was used for statistical analysis. Compar-
ison between categorical parameters was performed with a
v
2 test or Fischer’s exact test. For continuous parameters,
the two-sided Student t test was used. A value of p\0.05
was considered to be signiﬁcant.
Results
Of the 231 patients who underwent EUS-FNA, 18 (8%)
were excluded because no ﬁnal diagnosis was made
(Fig. 1). In total, 213 patients (152 men) with a median age
of 61 years (range = 23-88) were included (Table 1). Of
these, 92 (43%) patients had a history of malignancy, 51
(24%) had a strong clinical suspicion of malignancy, and
70 (33%) had no suspicion for or history of malignancy.
Accuracy
Cytology was diagnostic in 205 (96%) patients and non-
diagnostic in 8 patients (4%) (Table 2). Lymph node
localization and size and median number of passes to
obtain cytology are listed in Table 2. Diagnostic charac-
teristics are given in Table 3. No signiﬁcant differences
were found between the results for diagnostic or staging
EUS-FNA with an accuracy of 92 and 94%, respectively.
Table 4 presents the ﬁnal diagnoses of the false-negative
and inconclusive specimens.
Impact on management
A prepuncture diagnosis, available in 193 of 213 (91%)
procedures, was conﬁrmed by cytology in 119 (62%)
procedures and adjusted in 74 (38%) procedures (Table 2).
EUS-FNA had a positive impact on clinical management in
178 of 213 (84%) procedures (Table 5), particularly by
excluding malignant lymphadenopathy (35%) or inﬂuenc-
ing the decision to perform surgery (49%). Only a minority
of patients underwent surgery as a consequence of the
cytological result (n = 19), whereas in most cases surgery
was avoided (n = 85).
In 16 of 213 (8%) procedures, clinical management
was negatively affected by the cytological results by
Fig. 1 Flowchart of all EUS-FNA procedures for mediastinal
lymphadenopathy and their reference standards
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123Table 1 Baseline
characteristics of all patients
who underwent mediastinal
EUS-FNA with a ﬁnal diagnosis
Overall n (%) Diagnostic n (%) Staging n (%)
Patients 213 133 (62) 80 (38)
Median age (years) (range) 61 (23–88) 56 (23–86) 66 (40–88)
Male (% of patients) 152 (71) 92 (69) 60 (75)
History of malignancy (% of patients)
No 70 (33) 70 (53) 0 (0)
Clinical suspicion but no histological proof 51 (24) 23 (17) 28 (35)
Yes, with previous histological proof 92 (43) 40 (30) 52 (65)
Lung cancer 30 (33) 3 (8) 27 (52)
Esophageal cancer 14 (15) 0 (0) 14 (27)
Non-Hodgkin’s lymphoma 8 (9) 8 (20) 0 (0)
Breast cancer 7 (7) 6 (15) 1 (2)
Other 33 (36) 23 (57) 10 (19)
Previous investigation (% of patients)
CT 189(89) 127 (95) 62 (78)
EUS 16 (8) 1 (0.7) 15 (19)
PET 69 (36) 33 (25) 36 (45)
Table 2 Results of all EUS-
FNA procedures for mediastinal
lymphadenopathy with a ﬁnal
diagnosis
Overall n (%) Diagnostic n (%) Staging n (%)
Patients with a ﬁnal diagnosis 213 133 80
Prepuncture diagnosis 193 (91) 115 (86) 78 (98)
Conﬁrmed 119 (62) 74 (64) 45 (58)
Corrected 74 (38) 41 (36) 33 (42)
Location of lymph node
Aorta-pulmonary window 44 (21) 23 (17) 21 (26)
Subcarinal 113 (53) 76 (57) 37 (47)
Paratracheal 9 (4) 5 (4) 4(5)
Other 17 (8) 8 (6) 9 (11)
[1 lymph node station 30(14) 21(16) 9 (11)
Cytology
Malignant 87 (41) 44 (33) 43 (54)
Benign 118 (55) 82 (62) 36 (45)
Nondiagnostic 8 (4) 7 (5) 1 (1)
Mean size of lymph node in mm (± SD) 24 (±13) 26 (±14) 21 (±10)
Median number of passes (range) 3 (1–9) 3 (1–9) 3 (1–6)
Additional investigations performed 43 (20) 26 (20) 17(21)
Table 3 Diagnostic characteristics of EUS-FNA for mediastinal lymphadenopathy
n True
negative
True
positive
False
negative
Sensitivity
(%)
Speciﬁcity
(%)
NPV
(%)
PPV
(%)
p value
Overall 213 64 131 16
a 89 100 80 100
Diagnostic procedure 133 38 84 11 88 100 77 100 0.59
Staging procedure 80 28 47 5 90 100 85 100
Eloubeidi et al. [27] 246 123 108 11 92 99 93 99
NPV negative predictive value, PPV positive predictive value
Comparison for diagnostic accuracy in staging and diagnostic group (v
2 test)
a False-negative cytology included benign (8) and nondiagnostic (8) specimens
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123providing false-negative or inconclusive cytology. In 19
of 213 (9%) procedures, EUS-FNA did not affect patient
management despite adequate cytological results. In four
patients, the enlarged lymph node could not be detected
by EUS and a nonsuspicious lymph node was punctured
instead or there was confusion about which lymph node
was punctured after the procedure. Four patients were
referred for staging but subsequently refused further
treatment. Eleven patients underwent EUS-FNA although,
in retrospect, all these patients were already inoperable at
the time of EUS-FNA due to invasive tumor growth
(n = 4), distant metastases (n = 2), or known comorbid-
ity (n = 5). Most inoperable patients had esophageal
cancer (n = 8).
No signiﬁcant difference with respect to the impact on
management was found between diagnostic and staging
EUS-FNA (85 and 81%, respectively; p = 0.14).
Complications
Two perforations in 213 (0.9%) procedures occurred due to
a technical problem with the needle. One patient, known to
have brain metastases, developed mediastinitis. He was
treated with antibiotics and was discharged 25 days after
the procedure. He died 6 days later due to progression of
his malignancy. The second patient was treated with anti-
biotics and was discharged 6 days after EUS-FNA in good
clinical condition.
Cost reduction analysis
Table 6 gives the total cost of the actual diagnostic workup
versus the total cost of the alternative diagnostic workup,
including the costs of all the components of the workups. In
the alternative diagnostic workup, mediastinoscopy instead
of EUS-FNA would have been performed in 143 patients.
Since the complication rate of a cervical or parasternal
mediastinoscopy is estimated to be 2%, two complications
would have occurred in this cohort. The costs of the the-
oretical complications were assumed to be equal to the
costs of the complications that occurred in the actual fol-
low-up (€3,755; see Table 6). The total amount saved by
performing 213 EUS-FNA procedures was €100,593,
which results in average cost savings of €472 per patient.
Discussion
This study shows that the performance characteristics of
EUS-FNA in patients with mediastinal lymphadenopathy
performed in low-volume EUS centers are comparable to
those in studies from high-volume EUS centers. Despite
the relatively low case volume (213 cases in 6 years), our
testing characteristics were the same as those obtained in a
high-volume center by one very experienced endoscopist
(Table 3)[ 27]. The diagnostic accuracy of EUS-FNA for
mediastinal nodes in high-volume centers has been repor-
ted to be high (89–98%) [2–4, 8, 16, 27–29]. In most of
those studies, EUS-FNA was performed by only one or two
experienced endoscopists, which may well explain these
excellent results [4, 8, 16, 27–29]. In our study, EUS-FNA
procedures were performed by four endoscopists at two
centers, each of whom had performed fewer than 25 EUS-
FNA procedures before the start of the study. Since it has
been suggested that the results of EUS-FNA are directly
proportional to the experience of the endoscopist [30], our
study may be a more realistic reﬂection of EUS-FNA
results in normal daily clinical practice. A learning curve
with regard to diagnostic accuracy [18, 19, 21] could not be
detected in our study. This might be the result of the
Table 4 Final diagnosis in patients with false-negative (benign or
nondiagnostic) specimens after EUS-FNA for mediastinal
lymphadenopathy
False negative (8) Nondiagnostic (8)
Sarcoidosis (4) Sarcoidosis (6)
Tuberculosis (1) NSCLC (1)
Adenocarcinoma esophagus (1) Small cell lung cancer (1)
Gastric cancer (1)
Chronic lymhocytic leukemia (1)
NSCLC non-small-cell lung cancer
Table 5 Impact on clinical
management of EUS-FNA for
mediastinal lymphadenopathy
Overall
(n = 213)
Diagnostic
EUS-FNA
(n = 133)
Staging
EUS-FNA
(n = 80)
Positive impact (%) by providing tissue diagnosis 178 (84) 113 (85) 65 (81)
and inﬂuencing decision on surgery 104 (49) 42 (32) 62 (77)
and diagnosing an inﬂammatory disorder or reactive node 74 (35) 71 (53) 3 (4)
Negative impact (%) by providing 35 (16) 20 (15) 15 (19)
false-negative or inconclusive specimen 16 (7) 11 (8) 5 (7)
no effect on management despite adequate cytology 19 (9) 9 (7) 10 (12)
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123relatively low complexity of EUS-FNA of mediastinal
lymphadenopathy.
Interestingly, in 10 of 16 patients (63%) with false-
negative or nondiagnostic specimens, the ﬁnal diagnosis
turned out to be sarcoidosis (Table 4). This result raises the
question of whether cytology is sufﬁcient to diagnose sar-
coidosis, which is traditionally diagnosed by histology.
Although several studies have shown an accurate cytolog-
ical diagnosis in 86–94% of sarcoidosis cases, these results
were obtained mainly in small, selected patient populations
with a high pretest probability for sarcoidosis [31–34].
Interestingly, a recent study comparing cytological and
histological specimens showed signiﬁcantly better results
for histology [34/36 (94%) correct diagnoses] than for
cytology [28/32 (82%) correct diagnoses, p = 0.04] [35].
In most patients in our study (84%), EUS-FNA had a
positive impact on clinical management [26] since false-
negative or inconclusive cytological results occurred
infrequently (7%). However, the impact could have been
even higher. This is explained by the observation that in
another 9% of cases the impact was considered negative
despite adequate cytological specimens. In retrospect, the
indication for performing EUS-FNA in these patients was
incorrect since the clinical management of these patients
did not depend on this result. These were mostly patients
with distal esophageal cancer in whom mediastinal FNA
may be valuable for directing the appropriate surgical
approach (transthoracic versus transhiatal esophageal
resection) [17]. Nonetheless, EUS-FNA should be per-
formed only in patients who are already considered to be
clinically ﬁt to undergo a resection.
Previous studies on EUS-FNA of mediastinal lym-
phadenopathy focused mainly on lung cancer staging. It
has been shown that in 49–68% of patients with lung
cancer, surgery or additional surgical staging was avoided
as a consequence of the cytological result [8, 11]. A recent
randomized trial showed that adding EUS-FNA to the
conventional workup of lung cancer patients reduced the
number of futile thoracotomies from 25% in the conven-
tional workup to 9% in the workup with EUS-FNA [10].
Annema et al. [36] also reported that 16% of thoracotomies
were avoided by using EUS-FNA in addition to mediasti-
noscopy in preoperative staging. A few studies have
assessed the clinical impact of EUS-FNA in patients with
mediastinal lymphadenopathy of unknown origin [5–7].
Catalano et al. [5] found that EUS-FNA affected clinical
decision-making in 87% of cases in a series of 62 patients
with mediastinal lymphadenopathy of unknown cause.
These results are in line with our ﬁndings.
Until now, the evaluation of the cost-effectiveness of
EUS-FNA compared to other lymph node sampling
methods has been relatively uncommon [16, 23–25]. Elo-
ubeidi et al. [16] showed an average cost reduction of
$11,033 per patient by using EUS-FNA instead of medi-
astinoscopy as the primary staging tool in patients with
NSCLC. In our heterogeneous patient population, various
diagnostic tools such as mediastinoscopy or CT-guided
FNA would have been performed if EUS-FNA had not
been available. The use of EUS-FNA resulted in a cost
reduction of €472 per patient by avoiding other more
invasive and deﬁnitely more expensive procedures. The
absolute cost reduction for our patient population was
Table 6 Comparison of the cost of an alternative diagnostic workup (without EUS-FNA) and the actual diagnostic workup (by using EUS-FNA)
for mediastinal lymphadenopathy
Diagnostic tools Cost
a (€) Alternative workup Actual workup
Number of
investigations
Theoretical
cost (€)
Number of
investigations
Actual
cost (€)
EUS-FNA 175 0 0 213 37,275
Mediastinoscopy/parasternal mediastinotomy 961 143 137,423 15 14,415
Video-assisted thoracoscopy (VATS) 1,096 2 2192 4 4384
PET scan 998 4 3992 1 998
Upper endoscopy 102 4 408 5 510
FNA/biopsy with other method 76 14 1064 10 760
Bronchoscopy 294 29 8526 5 1470
Expectative 0 17 0 0 0
Complications of investigation 3755
b 2 7511 2 7511
Death through investigation 100,000
b 00 0 0
Total cost of alternative
workup (€)
161,116 Total cost of actual
workup (€)
60,523
a If necessary, pathology processing and interpretation, anesthesia, and hospital stay are included in costs
b Fixed costs for complications and death through complications were used for both theoretical and actual complications
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123substantially less pronounced compared to other cost
studies. This is probably because in our study the costs
saved by abstaining from surgery were not included in the
analysis. Furthermore, we did not include the costs of
additional investigations in the alternative workup, which
would probably have been performed in some patients
because of an inadequate diagnostic result. This would
have further increased the total cost difference between the
two diagnostic strategies in favor of EUS-FNA.
Two esophageal perforations occurred in our study pop-
ulation, resulting in a complication rate of 0.9%. Other
studiesthatprospectivelyassessedthesafetyofEUS-FNAin
various organshave reportedcomparable complicationrates
(0.3–2.2%)[37–39],withesophagealperforationaccounting
for 50% of complications in one study [38]. Since our
patientswerenotfollowedupafterEUS-FNAaccordingtoa
predeﬁned protocol, our complication rate might be an
underestimate. Furthermore, most studies on mediastinal
EUS-FNA do not report any complications at all, which
suggeststhatourcomplicationratemaybehigherthanthatof
mosthigh-volumecenters.Thismaywellreﬂectthefactthat
the endoscopists in our study were less experienced.
Our study has some limitations. The lack of histological
conﬁrmation in a large number of patients may reduce the
validity of these results. Although most studies in this ﬁeld
use long-term follow-up as a reference standard for cytol-
ogy results [2, 3, 27], this may give rise to a biased accu-
racy in favor of EUS-FNA. In addition, a retrospective
judgment of the impact on clinical management may
introduce classiﬁcation bias. Therefore, classiﬁcation was
performed independently by a panel consisting of a
researcher, a pulmonologist, and a gastroenterologist. To
compensate for classiﬁcation bias, special emphasis was
placed on a critical judgment of the indication for EUS-
FNA. Furthermore, the retrospective assessment of costs
saved by performing EUS-FNA was cumbersome as well
due to the heterogeneity of our population. Therefore, the
alternative diagnostic or staging work-up was determined
for each individual patient (taking into account indication
for EUS-FNA, medical history, and lymph node station)
and not for a diagnostic category.
Finally, in the theoretical workup we did not include the
use of endobronchial ultrasound-guided ﬁne-needle aspi-
ration (EBUS-FNA) because it was not available in our
institutions. Currently, EBUS-FNA might be a more elegant
way to analyze mediastinal lymphadenopathy compared to
mediastinoscopy [1, 40]. Performing EBUS-FNA instead of
mediastinoscopy in the theoretical workup might change
the outcome of the cost analysis by decreasing the number
of mediastinoscopies performed. Furthermore, some high-
volume EUS centers have shown that adding EBUS-FNA to
EUS-FNA can improve the diagnostic yield since both
methods are complementary, reaching different lymph node
stations [41, 42]. However, just like mediastinoscopy,
EBUS alone is hampered by the inability to sample the
lymph nodes in the aorta pulmonary window [1, 41].
In conclusion, our study demonstrated that EUS-FNA is
a valuable diagnostic tool to guide patient management and
reduces the costs of clinical evaluation in a large hetero-
geneous group of patients being analyzed for mediastinal
lymphadenopathy. Moreover, mediastinal EUS-FNA can
be performed in low-volume EUS-FNA centers without
compromising diagnostic accuracy.
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